# Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

> **NCT05486182** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **GE Healthcare** · enrollment: 153 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** 18F Fluoroestradiol Radiopharmaceutical with PET/CT

## Key facts

- **NCT ID:** NCT05486182
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-08
- **Primary completion:** 2025-04-18
- **Final completion:** 2026-01
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05486182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05486182, "Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05486182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*